Sumeet Kumar Yadav

Dr. Sumeet Kumar Yadav

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2024 in Medicina
Verified
Journal Article
Open access
PDF file
SYSumeet Kumar Yadav
Sumeet Kumar Yadav
GHGuleid Hussein
Guleid Hussein
BLBolun Liu
Bolun Liu
NVNikhil Vojjala
Nikhil Vojjala
MWMohamed Warsame
Mohamed Warsame
NJNitesh Kumar Jain
Nitesh Kumar Jain
Blood transfusion is a common therapeutic intervention in hospitalized patients. There are numerous indications for transfusion, including anemia and coagulopathy with deficiency of single or multiple coagulation components such as platelets or coagulation factors. Nevertheless, the practice of transfusion in critically ill patients has been controversial mainly due to a lack of evidence and the need to consider the appropriate clinical context for transfusion. Further, transfusion carries many risk factors that must be balanced with benefits. Therefore, transfusion practice in ICU patients has constantly evolved, and we endeavor to present a contemporary review of transfusion practices in this population guided by clinical trials and expert guidelines.

12 December 2023 in Medicina
Verified
Journal Article
Open access
PDF file
GHGuleid Hussein
Guleid Hussein
BLBolun Liu
Bolun Liu
SYSumeet Kumar Yadav
Sumeet Kumar Yadav
MWMohamed Warsame
Mohamed Warsame
Ramsha JamilRamsha Jamil
Ramsha Jamil
Syed Anjum KhanSyed Anjum Khan
Syed Anjum Khan
Therapeutic plasma exchange (TPE) is a treatment paradigm used to remove harmful molecules from the body. In short, it is a technique that employs a process that functions partially outside the body and involves the replacement of the patient’s plasma. It has been used in the ICU for a number of different disease states, for some as a first-line treatment modality and for others as a type of salvage therapy. This paper provides a brief review of the principles, current applications, and potential future directions of TPE in critical care settings.

19 March 2026 in Blood
Verified
Journal Article
Closed access
RLRebecca K. Leaf
Rebecca K. Leaf
JMJodi V. Mones
Jodi V. Mones
TSTushar Shenoy
Tushar Shenoy
MWMohamed Warsame
Mohamed Warsame
MBMarina Beltrami-Moreira
Marina Beltrami-Moreira
DLDavid E. Leaf
David E. Leaf
Immune checkpoint inhibitor–associated immune thrombocytopenia (ICI-ITP) has been described in case reports and small case series, but comprehensive data on its incidence, risk factors, clinical features, treatment, and outcomes are lacking. We reviewed medical records of all adults initiating ICI therapy between 2016 and 2023 at 29 US hospitals across 7 major cancer centers to identify patients with ICI-ITP. Multivariable logistic regression was used to identify risk factors, and Cox modeling was performed to assess the association between ICI-ITP, its severity, and mortality. Among 86 467 patients, ICI-ITP occurred in 214 (0.25%). Independent risk factors included lower baseline platelet count, combination ICI therapy, stage IV cancer, and additional immune-related adverse events. ICI-ITP occurred at a median of 8 weeks (interquartile range [IQR], 4-18) after ICI initiation, with a median nadir platelet count of 41 × 109/L (IQR, 17 × 109/L to 64 × 109/L). Patients were treated with glucocorticoids (n = 106 [49.5%]), immune globulin (n = 39 [18.2%]), and thrombopoietin receptor agonists (n = 29 [13.6%]). Recovery occurred in 161 patients (75.2%) at a median of 2.3 weeks (IQR, 1.0-5.3). Of 76 patients rechallenged with ICIs, 23 (30.3%) developed recurrent ICI-ITP. ICI-ITP and its severity were associated with higher all-cause mortality, with a nearly threefold increase in risk among patients with severe ICI-ITP than those without ICI-ITP (adjusted hazard ratio, 2.96 [95% confidence interval, 2.14-4.08]). These findings establish ICI-ITP as a rare but clinically significant complication of ICI therapy, provide, to our knowledge, the first large-scale description of its risk factors and clinical course, and underscore the importance of timely recognition and management.

28 August 2025 in Cancers
Verified
Journal Article
Open access
PDF file
SYSumeet Kumar Yadav
Sumeet Kumar Yadav
UJUtsav Joshi
Utsav Joshi
GHGuleid Hussein
Guleid Hussein
MWMohamed Warsame
Mohamed Warsame
BLBolun Liu
Bolun Liu
ASAmrit Singh
Amrit Singh
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by the clonal proliferation of myeloid precursors and rapid progression. Historically consisting of intensive chemotherapy, AML management has evolved significantly due to advances in molecular diagnostics and risk stratification. This review discusses current therapeutic paradigms in AML, emphasizing the growing role of personalized medicine across age and risk groups. For younger, fit patients, intensive regimens such as the “7 + 3” protocol remain the standard, often enhanced by targeted agents like FMS-like tyrosine kinase 3 (FLT3) and IDH inhibitors. Older or unfit individuals benefit from low-intensity treatments such as hypomethylating agents combined with venetoclax, now considered a frontline standard of care. The use of liposomal chemotherapy (CPX-351), measurable residual disease (MRD) monitoring, and maintenance therapy further refine post-remission strategies. Emerging therapies, including menin inhibitors, antibody–drug conjugates, and immunotherapies like CAR-T cells and vaccines, offer additional options, especially in relapsed/refractory settings. This comprehensive review outlines the current landscape and future directions in AML therapy, emphasizing the transition toward individualized, mutation-driven treatment strategies.

6 July 2020 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
AKAditya Kotecha
Aditya Kotecha
DRDeepa Raghavan
Deepa Raghavan
SYSumeet Kumar Yadav
Sumeet Kumar Yadav
ASAnupam A. Sule
Anupam A. Sule
CACamelia Arsene
Camelia Arsene

1 July 2024 in Minerva Medica
Verified
Journal Article
Closed access
SYSumeet Kumar Yadav
Sumeet Kumar Yadav
RLRoberto A. Leon-Ferre
Roberto A. Leon-Ferre
Article: Current treatment paradigms for triple-negative breast cancer - Minerva Medica 2024 Jul 17 - Minerva Medica - Journals